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Abstract: Background: functional gastrointestinal disorders (FGID) are common conditions in
children and adults, often associated with abnormalities of whole gut transit. Currently, transit tests
can be performed using several imaging methods, including tracking of radiopaque markers, gamma
scintigraphy with the use of radioisotopes, magnetic tracking methods, tracking of movement of
wireless motility capsules, and emerging magnetic resonance imaging (MRI) approaches. Objectives:
to review recent literature on diagnostic imaging techniques used to investigate whole gut transit
in FGIDs. Methods: a systematic review was carried out. The different techniques are described
briefly, with particular emphasis on contemporary literature and new developments, particularly in
the field of MRI. Conclusions: emerging MRI capsule marker methods are promising new tools to
study whole gut transit in FGIDs.
Keywords: imaging; transit; colon; MRI; constipation; irritable bowel syndrome; dysmotility;
small intestinal bacterial overgrowth
1. Introduction
Functional gastrointestinal disorders (FGID) are some of the most commonly diagnosed
conditions in gastroenterology and account for about 40% of all gastroenterology clinical practice [1].
These disorders can be associated with abnormalities of transit and diagnostic testing can be clinically
useful to detect abnormalities [2].
The Rome IV process provides consensus definitions and diagnostic criteria classifying FGIDs
according to the segment of gastrointestinal tract where the condition is believed to originate from [1,3].
Rome IV classifications were also developed for FGIDs observed in children and adolescents [4,5].
Constipation features prominently as a common complaint in multiple FGIDs (according to Rome
IV [3]). Three groups of bowel disorders (irritable bowel syndrome with predominant constipation
(IBS-C), functional constipation and opioid-induced constipation) are associated with constipation.
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Small intestinal bacterial overgrowth (SIBO) is another common disorder of the gastrointestinal tract.
It reflects excess presence of bacteria in the small bowel, and recent studies suggest SIBO can be
associated with altered gut transit [6].
Constipation can be caused by slow transit of chyme within the colon. Different factors can
contribute to this, including diet, lifestyle and medications [7]. Constipation can also signal the presence
of other underlying disorders such as diabetes, coeliac disease and cancer [8].
A recent review estimated the average prevalence of constipation at 16% worldwide [9]. In the
United States, the number of hospital emergency visits linked to constipation increased by 41.5%
between 2006 and 2011 [10]. Constipation is thought to be twice as common in women than in men [9].
Women at the postpartum stage (several weeks after pregnancy) are often affected by the condition,
with up to 25% of women reporting the incidence of constipation [11]. Constipation rates tend to be
substantially higher in the elderly population and reach up to 50–75%.
Most cases of constipation are caused by one of three general mechanisms: disordered and
obstructed defecation caused primarily by impaired rectal evacuation, irritable bowel syndrome with
constipation, and slow transit constipation [12]. These mechanisms differ substantially, even though
the general symptoms of constipation appear very similar. Proper treatment in each case calls for a
patient-specific differential diagnosis. This diagnosis remains challenging and about half of all patients
who complain of constipation remain unsatisfied with the treatment they receive [12].
Slow transit constipation, a reduced intestine motility caused by abnormalities of the enteric nerves,
accounts for 15–30% of all constipated patients, with up to 37% of constipated women affected [13].
Functional constipation in childhood is very common. Its prevalence has been estimated to be
14%, forming approximately 3% of all hospital paediatric referrals [14–18]. In the majority of paediatric
cases, constipation is not linked to specific clinical disorders but rather caused by changes in lifestyle
or diet [19]. Slow transit constipation accounts for approximately 10% of all paediatric cases [20].
Managing illness in these children is challenging, and the diagnosis often unclear and based mostly on
symptom reports [5,21]. An objective measure of the gut transit time could assist in stratifying the
patients and direct early selection of therapy. Gastrointestinal transit time in children is, however, not
often assessed using current methods due to the radiation dose involved, which is not suitable for
young patients due to their greater sensitivity to radiation than adults.
As the etiology of constipation is multifactorial, the treatment of constipation requires a clear
understanding and a differential diagnosis of its clinical causes [22]. Physical examination (abdominal
and rectal examinations) and various tests can be performed, including imaging studies of whole gut
transit time. Transit time in this context is the time taken by food and chyme to travel through the
gastrointestinal tract, thanks to complex propulsive mechanisms. Whole gut transit time (WGTT) is
defined as the combination of gastric emptying, small bowel transit time and colonic transit time [23].
The ideal technique for these measurements should be noninvasive and easily applicable for both
diagnostic and patient monitoring in the course of therapy. Currently, colonic transit can be performed
using several imaging methods, including the use of radiopaque markers, radioisotopes, methods to
track magnetic capsules or wireless devices and magnetic resonance imaging (MRI) approaches.
New MRI-based methods to measure and monitor the gastrointestinal transit are currently
emerging, with the possible benefits of the nonionising, cross-sectional imaging that MRI offers, which
is particularly suited to the paediatric population. The anatomy can be visualised in detail whilst
assessing transit.
2. Materials and Methods
A systematic search of the literature was carried out to identify publications describing imaging
studies of gastrointestinal transit. The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines were followed.
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The primary searches were carried out in Web of Science complemented by searches on Medline
and Embase engines using keywords relating to gastrointestinal transit and functional gastrointestinal
diseases. The search strategy is provided in Supplementary Materials Figure S1.
Studies were included in this review if they matched the predefined inclusion/exclusion criteria according
to the patients, intervention, comparator, outcomes, and study design (PICOS) tool as reported in Table 1.
Table 1. Patients, intervention, comparator, outcomes, and study design (PICOS).
Parameter Inclusion Criteria Exclusion Criteria
Participants
• Children and adults of any
age with functional
gastrointestinal disease of the
large bowel.
• Healthy children and adults
of any age who participated
in a study aimed at
developing a technology or
methods to measure whole
gut transit.
• Animal or in vitro studies.
Intervention
• Imaging methods to measure
whole gut transit time,
particularly new advances
in methods.
• Studies of effects of bowel cleansing or of
a specific drug or nutritional supplement
(e.g., fiber) or biofeedback/electrical
stimulation and intervention affecting
physiology and transit.
• Direct comparisons of older imaging
methods to measure whole gut transit
time against each other (e.g., manometry,
ultrasound, and X-ray appearance).
• Pure development of algorithms to
calculate whole gut transit time.
• Epidemiology, prevalence studies.
• Studies of specific sub-populations
(gender, age or race).
• Proctographic studies.
• Subcategorisation of patient groups based
on transit measurement.
• Studies of patient reported outcomes
scoring systems, symptoms, pain, stools
characteristics, colonic gas, gene
phenotyping, autoimmune disease, cells,
metabolism (e.g., 5HT), molecular biology,
transporter and serotonin effects.
Comparator • Not applicable • Not applicable
Outcomes • Imaging methods to measure
whole gut transit. • Not applicable
Study design
• Randomised controlled trials
• Quasi-experimental studies
(nonrandomised controlled
trials, before-and-after,
interrupted time series)
• Observational studies
(prospective and
retrospective). Studies
published in peer-review
journals or in the
grey literature.
• Case reports, reviews or systematic
literature reviews and qualitative studies,
opinion pieces, editorials,
• Comments, news, and letters.
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Duplicates were removed automatically using EndNote reference management software.
The included records were then screened by the title, abstract, and full text by two authors (H.S. and
L.M.). Once a paper was found to fit the eligibility criteria, its references were, in turn, searched in
order to find new papers that were previously missed.
Each included study was assessed for potential risk of bias (for example from the study design
and reporting) by two researchers independently (H.S. and R.S.) using the ROBINS-I (Risk Of Bias In
Non-Randomized Studies-of Interventions) tool [24,25]. Seven domains of bias were evaluated and the
preintervention domains were biased due to confounding and bias in selection of participants into the
study. The intervention bias domain was biased in classification of interventions. The postintervention
domains were biased due to deviations from intended interventions, bias due to missing data, bias in
measurement of outcomes, and bias in selection of the reported result. Each domain consisted of 3–8
signaling questions. If the signaling questions in every domain was answered with “No/Probably No”,
the study was considered to be at low risk of bias and no further signaling questions were considered.
If one or more questions were answered by “Yes/Probably Yes”, there was a potential marker for a risk
of bias and further questions related to this domain were assessed. Any disagreement was resolved
through discussion. The scores are reported in Supplementary Materials Figure S2. Finally, data about
the different diagnostic approaches were collected from each study and extracted into a Microsoft
Excel spreadsheet.
3. Results
3.1. Systematic Literature Search
The searches yielded 1415 records from the three databases (Figure 1). The articles were all written
in English, except for two articles in Chinese that had an English abstract that later led to exclusion.
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3.2. Selection of Literature
The 964 articles remaining after duplication removal were screened by title or abstract. This led
to 98 records being selected for full text screening. The full text screening exercise led to 24 papers
being excluded as they did not meet the inclusion criteria, 7 were found to be irrelevant to the review,
11 were review papers and 8 case reports were not included in the review. In total, 48 papers were
subjected to this systematic review.
4. Results of the Literature Search
From the 48 papers reviewed, different diagnostic approaches were considered, as discussed
below and summarised in Table 2.
Table 2. Diagnostic approaches comparison. Note: MRI = magnetic resonance imaging.
Diagnostic Approaches Advantages Disadvantages
X-ray Radiopaque Markers
• Noninvasive
• Easily performed test
• Inexpensive
• Ionising radiation exposure
• Two-dimensional radiographs where
loops of the bowel can overlap and
segments can be difficult to
distinguish, therefore the location of
the markers can be difficult to assign
• Lack of standardisation
across centers
Gamma scintigraphy
• A well validated method that
provides accurate
quantitative data for
colonic transit
• Noninvasive, relatively rapid
test over 48 to 72 h to
evaluate colonic transit
• Ionising radiation exposure
• Multiple image acquisition over
consecutive days
• Limited availability of equipment
• Costs
• Radioactive materials (short-lived
radioactive isotopes)
Tracking systems
• No ionising radiation
• Fully ambulatory as it uses a
body-borne detection system
• Colorectal length can
be measured
• High spatial and
temporal resolution
• Continuous monitoring
of transit
• Large sized capsule, may be difficult
to swallow
• Possibility of capsule retention,
especially in young children
Magnetic Resonance
Imaging
• No ionising radiation
• Excellent soft tissue contrast
and image resolution
• Short scan times
• Diffusion of
equipment worldwide
• Contraindication for MRI (e.g., metal
implants in the body)
• Cost
4.1. X-ray Radiopaque Markers
Traditional approaches include abdominal X-ray. A plain abdominal X-ray can provide important
information on transit when combined with tracking ingested markers, such as the radiopaque marker
(ROM) method (Figure 2) [27] or barium swallow-based methods [28–30].
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Figure 2. A plain abdominal X-ray image of radiopaque markers (ROMs) in the colon of a patient
with constipation.
In the ROM test, one or more capsules containing (~20–50) plastic markers are ingested. The plastic
markers contain barium salts, which provide X-ray contrast and make them visible in X-rays.
An abdominal radiograph is performed at set time points over the subsequent days. The capsules
dissolve and individual markers travel through the upper gastrointestinal tract, enter the colon and
gradually move through it. Quantification of whole gut transit time is subsequently performed using
simple calculations that assume a steady state loading of the bowel and assign a set amount of time
for each marker detected in the gut at the time of imaging [31]. The X-ray film can also be divided
anatomically using straight lines to assess segmental colonic transit, for example dividing the distal
bowel into right colon, left colon and rectosigmoid [32].
The original method of Metcalf [31] used ingestion of 20 ROM markers each day for 3 days
followed by an X-ray taken on day 4 and one taken on day 7. The method has been used throughout
the years, including in children with defecation disorders [33]. Many different variants of the technique
have been proposed. One “saturation” method uses 10 ring shaped markers ingested each day for 6
days with the addition of ingestion of 20 markers with a different rod shape on days 4, 5 and 6, followed
by an X-ray on day 7 [34]. The authors also noted the importance of maintaining a similar time of the
day for both ingestion of the markers and imaging in order for the whole gut transit time (WGTT)
calculations to be applied correctly. A similar method requiring ingestion only of 10 markers each day
for 6 days followed by an X-ray on day 7 was also used [32]. Other methods involved ingestion of a
single dose of 20 ROMs and repeated daily X-ray until all markers were evacuated, but not continued
if markers were still detected after 7 days [35]. The type of markers used also varies substantially,
including rings, rods and also barium balls [36].
In a simple variant of the test, the retention of 20% or more of the markers 5 days after administration
is considered indicative of slow transit constipation [37].
Different populations may have shorter average transit times and require an adaptation of the
marker methods shown in Western populations. For example, in a study of functional constipation in
Indian patients, the participants were asked to ingest a capsule containing 5 markers at time 0, 12 and
24 h followed by X-ray at 36 h after the first ingestion, showing a colon transit time much shorter than
in the Western populations [38].
Another version of this technique involves the use of multiple capsules with markers of different
geometric shapes. The capsules with markers are taken daily for three days, and abdominal X-rays are
performed once or twice (usually 4 days and 7 days after administration). The use of differently shaped
markers (usually various types of rings, such as O-rings, D-rings and tri-rings) allows one to visualise
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the daily movements of the markers through the gastrointestinal tract more precisely. The approach is
used for both routine measurements of gastrointestinal transit time.
A barium enema followed by an X-ray film 24 h later has also been used to study colonic transit
in children with constipation [28,29]. The method is more invasive, as it involves enema procedures
and does not correlate strongly with an X-ray ROM test, with Spearman’s r being in the order of 0.4.
A small amount of barium delivered orally was also together with X-ray to measure the transit of a
material more similar to chyme than nondigestible objects, such as ROMs [30]. The authors concluded
that the small oral barium transit was slower than the ROMs and that it might provide a more reliable
method, though it did not attract many citations.
Despite the variations in type and amount of markers ingested, the ROM method is simple
and has been popular for over 4 decades. It is often used as the “gold standard” to validate new
methods. For example, ROM whole gut transit tests were used to compare against the new wireless
motility capsule (SmartPill®) in patients with chronic constipation and in healthy volunteers [39,40].
This wireless capsule measures transit not by imaging, but indirectly from changes in luminal pH [41].
The X-ray images are two-dimensional projections with poor definition of the anatomy, which may
create problems in correctly identifying the specific location of markers within the GI tract. The test
requires a high level of compliance from patients (i.e., the marker capsules should be taken as
instructed). The radiation exposure due to multiple X-rays further limits the usefulness of these
techniques, particularly in investigating the causes of constipation in children and pregnant women.
Another limitation of the X-ray ROM method is that when two-dimensional radiographs are taken,
loops of the bowel can overlap, and therefore the markers located in one part of the bowel can be
mistaken for being located in a different segment.
4.2. Gamma Scintigraphy
Gamma scintigraphy is another technique that has long been used to study colonic transit [42,43],
including within paediatric population, [44]. The method uses a γ-emitting radioactive isotope.
Different isotopes have been used, including 99Tc [45], 111In [46,47] or 67Ga [48–50]. The isotopes
are administered in a nondigestible or digestible capsule. Subsequent gamma-scintigraphy images
(Figure 3) are then obtained at several time points using a large-field-of-view gamma camera.
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Comparing images allows one to establish the speed of movement of the radioactive label through
the colon. A variety of methods to deliver the isotopes orally have been proposed. These include
a water drink [51,52], a cellulose preparation [53,54], activated carbon [45], minicontainers [55],
capsules [52,56,57] and polystyrene pellets [58].
Physiological differences and variation in motor function between individuals can be reflected
in variation in the measurement, which otherwise has good reproducibility [59]. The scintigraphic
transit time studies can provide the endpoints to evaluate experimental therapies [60]. The technique
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requires specialist equipment and access to fairly short-lived radioactive isotopes, and thus is limited
to a relatively small number of specialised institutions. The use of radioactive materials is an obvious
disadvantage, due to the effects of ionising radiation. For this reason, the technique is not well suited
for diagnostic investigations of children and pregnant women.
Scintigraphy transit tests were also used to compare against the new wireless motility capsule
(SmartPill®) [62].
4.3. Tracking Systems
An alternative approach involves the use of magnetic or wireless capsules as the markers of transit.
In the magnetic tracking system approach [63,64], a small magnet is ingested, and its movement
through the GI system is tracked using one or more external superconducting quantum interference
devices (SQUIDs), which are very sensitive magnetic sensors. The technique allows reliable
measurements of gastric, colonic and total transit time without exposure to radiation. The high
resolution of magnetic tracking systems allow the study of GI transit in patients with good detail [65].
The specific details of the colonic propulsive dynamics have also been investigated using magnetic
tracking [66]. The magnetic tracking system requires magnetic field sensors that are not common, and
so far the method remains mostly a research tool.
A more advanced magnetic tracking system (Figure 4) uses a wireless telemetric capsule (diameter,
8 mm; length, 21 mm) incorporating a battery and an electromagnet. Following activation, the capsule
constantly emits electromagnetic signals that are detected and analysed by a specialised 3D transit
system and software [67–70]. This method has the advantage of being fully ambulatory, as it uses a
body-borne detection system. In addition to transit, colorectal length has also been measured using
this system [69].
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Magnetic marker monitoring systems can be used for studying the transit through the GI tract as
well as for establishing the fate of oral dosage forms inside it. This is important for targeting delivery of
drugs to specific parts of the gastrointestinal tract, including the colon. Small particles of ferromagnetic
iron oxide magnetite (Fe3O4) can be incorporated into the solid dosage forms, and their transit through
the GI tract can be monitored using the magnetic tracking system. The net magnetic moment of the
particles within the solid form generates a dipole field easily detectable by the system. Disintegration
of the dosage leads to the loss of this dipole, as the magnetic particles become reoriented. The timing
and anatomic location of this transition points to the position of the GI tract, where the drug becomes
released from the solid form [65]. As this method has high spatial (few millimeters) and temporal
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(milliseconds) resolution, it allows for continuous monitoring of transit, and the release of active
pharmaceuticals from the extended release dosage forms can also be studied in detail.
4.4. Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) provides a number of significant advantages over X-ray
and gamma scintigraphy, such as the lack of radiation exposure and an excellent soft tissue contrast.
The MRI methods are noninvasive and typically are not associated with health hazards, except for the
classic contraindications for MRI, such as having certain metal implants in the body. The cost of MRI
investigation is often cited as one of its major limitations. However, with the development and wider
availability of MRI scanners, the costs tend to decrease. The modern instruments allow fast acquisition
of information, sometimes with a single breath-hold being sufficient to cover the whole abdomen.
This helps to avoid motion artefacts encountered when using longer acquisition times. High-resolution
and multiplanar capability are other advantages of this technique. In addition, the lack of ionising
radiation is a further advantage when dealing with more vulnerable patients, such as pregnant women
or children. The use of other invasive approaches can also be problematic in the geriatric population.
Whole gut transit time can be measured with MRI using capsule markers filled with water or a
contrast agent, such as gadolinium (Figure 5). MRI does not image directly the outline of the capsules’
shell but images the filling of the capsule. Measurements taken using these markers showed good
correlation with the results obtained by other methods. MRI of the whole gut transit time measured
using marker capsules (20 mm × 7 mm dimensions) filled with water doped with a gadolinium-based
contrast agent were compared against the radiopaque markers technique [71,72]. The capsules were
imaged once at 24 h after ingestion to determine their weighted average position score (WAPS) in the
gut. The correlation coefficient r between two sets of measurements was 0.85, demonstrating that two
techniques are highly consistent and provide similar outcomes.Diagnostics 2019, 9, x FOR PEER REVIEW 10 of 16 
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Figure 5. Magnetic resonance imaging (MRI) showing five MRI marker capsules in the colon (indicated
by close arrows). Reproduced with permission from [71]; published by John Wiley & Sons, 1994.
The MRI capsules method was applied in studies of adult constipation, whereby whole gut
transit measured by MRI was significantly slower for patients with functional constipation compared
with healthy controls (p < 0.01) [73], and for irritable bowel syndrome with constipation compared
with healthy controls (p < 0.01 [73] and p < 0.03 [74]). Similarly, in another study healthy volunteers
swallowed 5 MRI marker capsules (overall outer dimensions 23.9 mm × 6.0 mm) containing a saline
water solution doped with gadolinium contrast agent [75]. The capsules were imaged successfully
in the GI tract of healthy volunteers at 7 different time points up to 60 h after ingestion to determine
their distribution in the GI tract. Another study measured the whole gut transit time in two groups of
participants, one with normal gut function and one with slow transit constipation [76]. Both radiopaque
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markers and gadolinium-based cylindrical marker capsules (15 mm × 0.5 mm dimensions) were used.
The correlation coefficients between these two methods were 0.88–0.89 for both groups of participants,
suggesting again that MRI can provide a good estimate of gut transit time in both healthy participants
and patients with constipation.
Direct oral ingestion of a single-dose, concentrated small drink bolus of gadolinium contrast agent
was used in three healthy volunteers with an unprepared bowel [77]. The progress of the bolus though
the gastrointestinal system was imaged at 12 h intervals for up to 96 h.
An interesting alternative to standard water proton MRI imaging of intestinal transit is the tracking
of 19F-fluorine-labelled capsules (11.5 mm × 7.2 mm dimensions) (Figure 6). Fluorine-based imaging
methods provide relatively good sensitivity compared with the more common methods based on the
detection of the hydrogen proton signal (1H). Taking into account that natural occurrence of fluorine in
the human body is close to zero, the detection of the fluorine signal allows for positive detection and
contrast. In one study [78], the movement of fluorine-containing capsules ingested with a meal was
monitored in participants over extended time periods (up to 1–1.5 h) while they remained in a supine
position inside the scanner. This approach, in combination with high resolution anatomical reference
scans, allowed accurate visualisation of the capsules’ journey inside the lumen. The 19F MRI, however,
requires dedicated receiver coils and multinuclear transmitter and receiver hardware, which are not
common and mostly based in a few research laboratories.Diagnostics 2019, 9, x FOR PEER REVIEW 11 of 16 
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Figure 6. Anatomical reference images of 19F capsule positions and the fitted intestinal course for
(a) subject A and (b) subject B. Stomach (S), gall bladder (G) and small intestine (I) are denoted in
the figure. The color code reflects the time course of the two capsules. Reproduced with permission
from [78]; published by John Wiley & Sons, 1984.
An interesting Single-photon Emission Computed Tomography/ Magnetic Resonance SPECT/MR
study followed the transit through the gut of a capsule containing both a 153Sm label for SPECT and a
Gd- oped water solution for MRI, which allowed fused imaging of the two methodologies [79].
An a ditional advantage of MRI is that a n mber of parameters of GI motor fu ction can be derived
from a single MRI study of a patient, some of which would otherwise require separate techniques and
a pointments. In addition to GI transit time, MRI can vis alise anatomy, measure colonic volume,
colonic wall ovement (motility), freely mobile water content, chyme relaxometry, gas content and
abnormalities of colonic wall thickness [73,74,80,81]. Recently, the MRI tagging technique helped to
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visualise the movement of colonic chyme in subjects with and without constipation [12]. These new
MRI methods have been developed in recent years. There are, however, still limitations associated
with them and barriers to adoption in the clinical arena, and the need for further validation and
harmonisation of methods across sites remains.
5. Conclusions
Identification and treatment of the FGIDs remains a challenging task for practitioners.
These functional diseases can be a manifestation of multiple underlying conditions, often with
very similar symptoms. The development of novel imaging techniques in recent decades has provided
the opportunity to provide objective measures of function, such as gut transit, which could help
diagnosis and management.
The methods and contemporary literature on imaging gastrointestinal transit were briefly reviewed
here. More traditional X-ray and gamma scintigraphy methods are still very valuable, and their
advantages and limitations were described previously (for example [2,82–84]). There is an unmet
need for a simple and widely applicable method to provide objective measurements of gastrointestinal
transit time in young patients without exposing them to ionising radiation.
New MRI methods are emerging as promising tools to study gastrointestinal transit in FGIDs.
We can expect most of the future GI transit imaging developments to come from MRI. The technological
challenges of automated methods of data processing will be overcome with improved algorithms and
machine learning. This will remove the issues of the use of semiautomated and manual approaches
relying on the availability and skills of highly trained staff. Commercial products will enable the
translation of these MRI techniques, also addressing the issue of standardisation.
Supplementary Materials: The following are available online at http://www.mdpi.com/2075-4418/9/4/0221/s1.
Author Contributions: All authors contributed to the conceptualisation, writing and editing of this review.
In addition: information specialist and database searches, R.S.; screening of results, H.S. and L.M.; risk of bias
analysis, H.S. and R.S.
Funding: H.S. is funded by an academic scholarship from the Ministry Of Health, Civil Service Commission,
Kuwait. This review work received no other external funding.
Conflicts of Interest: L.M. is the first author of patents and the principal investigator in research grants relating to
MRI measurement of gastrointestinal transit. The other authors declare no conflict of interest.
References
1. Tack, J.; Drossman, D.A. What’s new in Rome IV? Neurogastroenterol. Motil. 2017, 29. [CrossRef] [PubMed]
2. Rao, S.S.C.; Camilleri, M.; Hasler, W.L.; Maurer, A.H.; Parkman, H.P.; Saad, R.; Scott, M.S.; Simren, M.;
Soffer, E.; Szarka, L. Evaluation of gastrointestinal transit in clinical practice: Position paper of the American
and European Neurogastroenterology and Motility Societies. Neurogastroenterol. Motil. 2010, 23, 8–23.
[CrossRef] [PubMed]
3. Drossman, D.A. Functional gastrointestinal disorders: History, pathophysiology, clinical features, and Rome
IV. Gastroenterology 2016, 150, 1262–1279. [CrossRef] [PubMed]
4. Koppen, I.J.; Nurko, S.; Saps, M.; Di Lorenzo, C.; Benninga, M.A. The pediatric Rome IV criteria: what’s
new? Expert Rev. Gastroenterol. Hepatol. 2017, 11, 193–201. [CrossRef]
5. Hyams, J.S.; Di Lorenzo, C.; Saps, M.; Shulman, R.J.; Staiano, A.; van Tilburg, M. Childhood functional
gastrointestinal disorders: Child/adolescent. Gastroenterology 2016, 150, 1456–1468. [CrossRef]
6. Suri, J.; Kataria, R.; Malik, Z.; Parkman, H.P.; Schey, R. Elevated methane levels in small intestinal bacterial
overgrowth suggests delayed small bowel and colonic transit. Medicine 2018, 97. [CrossRef]
7. Basilisco, G.; Coletta, M. Chronic constipation: A critical review. Dig. Liver Dis. 2013, 45, 886–893. [CrossRef]
8. Bharucha, A.E.; Pemberton, J.H.; Locke, G.R. American Gastroenterological Association Technical Review on
Constipation. Gastroenterology 2013, 144, 218–238. [CrossRef]
9. Forootan, M.; Bagheri, N.; Darvishi, M. Chronic constipation. Medicine 2018, 97, e10631. [CrossRef]
Diagnostics 2019, 9, 0221 12 of 15
10. Sommers, T.; Corban, C.; Sengupta, N.; Jones, M.; Cheng, V.; Bollom, A.; Nurko, S.; Kelley, J.; Lembo, A.
Emergency Department Burden of Constipation in the United States from 2006 to 2011. Am. J. Gastroenterol.
2015, 110, 572–579. [CrossRef]
11. Turawa, E.B.; Musekiwa, A.; Rohwer, A.C. Interventions for treating postpartum constipation.
Cochrane Database Syst. Rev. 2014. [CrossRef]
12. Pritchard, S.E.; Paul, J.; Major, G.; Marciani, L.; Gowland, P.A.; Spiller, R.C.; Hoad, C.L. Assessment of
motion of colonic contents in the human colon using MRI tagging. Neurogastroenterol. Motil. 2017, 29, e13091.
[CrossRef] [PubMed]
13. Frattini, J.; Nogueras, J. Slow Transit Constipation: A Review of a Colonic Functional Disorder. Clin. Colon
Rectal Surg. 2008, 21, 146–152. [CrossRef]
14. Yong, D.; Beattie, R.M. Normal bowel habit and prevalence of constipation in primary school children.
Ambul. Child Health 1998, 4, 277–282.
15. Afzal, N.A.; Tighe, M.P.; Thomson, M.A. Constipation in children. Ital. J. Pediatr. 2011, 37. [CrossRef]
[PubMed]
16. van den Berg, M.M.; Benninga, M.A.; Di Lorenzo, C. Epidemiology of childhood constipation: A systematic
review. Am. J. Gastroenterol. 2006, 101, 2401–2409. [CrossRef] [PubMed]
17. Robin, S.G.; Keller, C.; Zwiener, R.; Hyman, P.E.; Nurko, S.; Saps, M.; Di Lorenzo, C.; Shulman, R.J.;
Hyams, J.S.; Palsson, O.; et al. Prevalence of Pediatric Functional Gastrointestinal Disorders Utilizing the
Rome IV Criteria. J. Pediatr. 2018, 195, 134–139. [CrossRef]
18. Scarpato, E.; Kolacek, S.; Jojkic-Pavkov, D.; Konjik, V.; Zivkovic, N.; Roman, E.; Kostovski, A.; Zdraveska, N.;
Altamimi, E.; Papadopoulou, A.; et al. Prevalence of Functional Gastrointestinal Disorders in Children
and Adolescents in the Mediterranean Region of Europe. Clin. Gastroenterol. Hepatol. 2018, 16, 870–876.
[CrossRef]
19. Colombo, J.M.; Wassom, M.C.; Rosen, J.M. Constipation and Encopresis in Childhood. Pediatr. Rev. 2015, 36,
392–402. [CrossRef]
20. Yik, Y.I.; Hutson, J.; Southwell, B. Home-Based Transabdominal Interferential Electrical Stimulation for Six
Months Improves Paediatric Slow Transit Constipation (STC). Neuromodulation Technol. Neural Interface 2017,
21, 676–681. [CrossRef]
21. Benninga, M.A.; Nurko, S.; Faure, C.; Hyman, P.E.; Roberts, I.S.; Schechter, N.L. Childhood Functional
Gastrointestinal Disorders: Neonate/Toddler. Gastroenterology 2016, 150, 1443–1455. [CrossRef] [PubMed]
22. Jamshed, N.; Lee, Z.E.; Olden, K.W. Diagnostic Approach to Chronic Constipation in Adults.
Am. Fam. Physician 2011, 84, 299–306. [PubMed]
23. Lee, Y.Y.; Erdogan, A.; Rao, S.S.C. How to Assess Regional and Whole Gut Transit Time With Wireless
Motility Capsule. J. Neurogastroenterol. Motil. 2014, 20, 265–270. [CrossRef] [PubMed]
24. Sterne, J.A.C.; Hernan, M.A.; Reeves, B.C.; Savovic, J.; Berkman, N.D.; Viswanathan, M.; Henry, D.;
Altman, D.G.; Ansari, M.T.; Boutron, I.; et al. ROBINS-I: A tool for assessing risk of bias in non-randomised
studies of interventions. BMJ Br. Med. J. 2016, 355. [CrossRef]
25. Sterne, J.A.C.; Savovic, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.;
Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A revised tool for assessing risk of bias in randomised trials.
BMJ Br. Med. J. 2019, 366. [CrossRef] [PubMed]
26. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Grp, P. Preferred Reporting Items for Systematic Reviews
and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009, 6. [CrossRef]
27. Hinton, J.M.; Lennardj, J.; Young, A.C. A new method for studying gut transit times using radiopaque
markers. Gut 1969, 10, 842–847. [CrossRef]
28. Hwan Bae, S. Value of 24-hour delayed film of barium enema for colon transit function in young children
with constipation. Am. J. Gastroenterol. 2014, 109, S594. [CrossRef]
29. Yoo, H.Y.; Son, J.S.; Park, H.W.; Kwak, B.O.; Kim, H.S.; Bae, S.H. Value of 24-hour Delayed Film
of Barium Enema for Evaluation of Colon Transit Function in Young Children with Constipation.
J. Neurogastroenterol. Motil. 2016, 22, 483–489. [CrossRef]
30. Yuan, W.; Zhang, Z.; Liu, J.; Li, Z.; Song, J.; Wu, C.; Wang, G. Simplified assessment of segmental
gastrointestinal transit time with orally small amount of barium. Eur. J. Radiol. 2012, 81, 1986–1989.
[CrossRef]
Diagnostics 2019, 9, 0221 13 of 15
31. Metcalf, A.M.; Phillips, S.F.; Zinsmeister, A.R.; Maccarty, R.L.; Beart, R.W.; Wolff, B.G. Simplified assessment
of segmental colonic transit. Gastroenterology 1987, 92, 40–47. [CrossRef]
32. Ansari, R.; Sohrabi, S.; Ghanaie, O.; Amjadi, H.; Merat, S.; Vahedi, H.; Khatibian, M. Comparison of colonic
transit time between patients with constipation-predominant irritable bowel syndrome and functional
constipation. Indian J. Gastroenterol. 2010, 29, 66–68. [CrossRef] [PubMed]
33. Benninga, M.A.; Buller, H.A.; Staalman, C.R.; Gubler, F.M.; Bossuyt, P.M.; Van der Plas, R.N.; Taminiau, J.A.J.M.
Defaecation disorders in children, colonic transit time versus the Barr-score. Eur. J. Pediatr. 1995, 154, 277–284.
[CrossRef] [PubMed]
34. Abrahamsson, H.; Antov, S.; Bosaeus, I. Gastrointestinal and colonic segmental transit time evaluated by a
single abdominal X-ray in healthy subjects and constipated patients. Scand. J. Gastroenterol. Suppl. 1988, 23,
72–80. [CrossRef]
35. Bouchoucha, M.; Devroede, G.; Arhan, P.; Strom, B.; Weber, J.; Cugnenc, P.H.; Denis, P.; Barbier, J.P. What is
the meaning of colorectal transit time measurement? Dis. Colon Rectum 1992, 35, 773–782. [CrossRef]
36. Enqiang, L.; Chunying, Z. Colonic transit time study in patients with chronic constipation using a radiopaque
marker. Am. J. Gastroenterol. 2017, 112, S1457. [CrossRef]
37. Evans, R.C.; Kamm, M.A.; Hinton, J.M.; Lennardjones, J.E. The normal range and simple diagram for
recording whole gut transit time. Int. J. Colorectal Dis. 1992, 7, 15–17. [CrossRef]
38. Bhate, P.A.; Patel, J.A.; Parikh, P.; Ingle, M.A.; Phadke, A.; Sawant, P.D. Total and Segmental Colon Transit
Time Study in Functional Constipation: Comparison with Healthy Subjects. Gasteroenterol. Res. 2015, 8,
157–159. [CrossRef]
39. Rao, S.S.C.; Kuo, B.; McCallum, R.W.; Chey, W.D.; DiBaise, J.K.; Hasler, W.L.; Koch, K.L.; Lackner, J.M.;
Miller, C.; Saad, R.; et al. Investigation of Colonic and Whole-Gut Transit with Wireless Motility Capsule and
Radiopaque Markers in Constipation. Clin. Gastroenterol. Hepatol. 2009, 7, 537–544. [CrossRef]
40. Camilleri, M.; Thorne, N.K.; Ringel, Y.; Hasler, W.L.; Kuo, B.; Esfandyari, T.; Gupta, A.; Scott, S.M.;
McCallum, R.W.; Parkman, H.P.; et al. Wireless pH-motility capsule for colonic transit: Prospective
comparison with radiopaque markers in chronic constipation. Neurogastroenterol. Motil. 2010, 22, 874.
[CrossRef]
41. Kuo, B.; Maneerattanaporn, M.; Lee, A.A.; Baker, J.R.; Wiener, S.M.; Chey, W.D.; Wilding, G.E.; Hasler, W.L.
Generalized transit delay on wireless motility capsule testing in patients with clinical suspicion of
gastroparesis, small intestinal dysmotility, or slow transit constipation. Dig. Dis. Sci. 2011, 56, 2928–2938.
[CrossRef] [PubMed]
42. Bonapace, E.S.; Maurer, A.H.; Davidoff, S.; Krevsky, B.; Fisher, R.S.; Parkman, H.P. Whole gut transit
scintigraphy in the clinical evaluation of patients with upper and lower gastrointestinal symptoms.
Am. J. Gastroenterol. 2000, 95, 2838–2847. [CrossRef] [PubMed]
43. Charles, F.; Camilleri, M.; Phillips, S.F.; Thomforde, G.M.; Forstrom, L.A. Scintigraphy of the whole gut:
Clinical evaluation of transit disorders. Mayo Clin. Proc. 1995, 70, 113–118. [CrossRef] [PubMed]
44. Carmo, R.L.M.L.; Oliveira, R.P.M.; Ribeiro, A.E.A.; Lima, M.C.L.; Amorim, B.J.; Ribeiro, A.F.; Ramos, C.D.;
Bustorff-Silva, J.M.; Lomazi, E.A. Colonic transit in children and adolescents with chronic constipation.
J. Pediatr. 2015, 91, 386–391. [CrossRef]
45. Vlajkovic, M.; Rajic, M.; Stevic, M.; Zivkovic, V.; Dordevic, I.; Matovic, M. Assessment of functional
constipation in children by means of Tc-99m-DTPA-activated carbon. Eur. J. Nucl. Med. Mol. Imaging 2014,
41, S588. [CrossRef]
46. Krevsky, B.; Maurer, A.H.; Fisher, R.S. Patterns of colonic transit in chronic idiopathic constipation.
Am. J. Gastroenterol. 1989, 84, 127–132.
47. van der Sijp, J.R.; Kamm, M.A.; Nightingale, J.M.; Britton, K.E.; Mather, S.J.; Morris, G.P.; Akkermans, L.M.;
Lennard-Jones, J.E. Radioisotope determination of regional colonic transit in severe constipation: Comparison
with radio opaque markers. Gut 1993, 34, 402–408. [CrossRef]
48. Bartholomeusz, D.; Chatterton, B.E.; Bellen, J.C.; Gaffney, R.; Hunter, A. Segmental colonic transit after
oral 67Ga-citrate in healthy subjects and those with chronic idiopathic constipation. J. Nucl. Med. 1999, 40,
277–282.
49. Cheng, K.-Y.; Tsai, S.-C.; Lin, W.-Y. Gallium-67 activated charcoal: A new method for preparation of
radioactive capsules for colonic transit study. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 907–911. [CrossRef]
Diagnostics 2019, 9, 0221 14 of 15
50. Asli, I.N.; Ehsani, M.J.; Javadi, H.; Jallalat, S.; Assadi, M. Colon transit scintigraphy in the idiopathic
constipated patients by 67Ga-citrate. Iran. J. Nucl. Med. 2010, 18, 64.
51. Roberts, J.P.; Newell, M.S.; Deeks, J.J.; Waldron, D.W.; Garvie, N.W.; Williams, N.S. Oral [111In]DTPA
scintigraphic assessment of colonic transit in constipated subjects. Dig. Dis. Sci. 1993, 38, 1032–1039.
[CrossRef] [PubMed]
52. Stubbs, J.B.; Valenzuela, G.A.; Stubbs, C.C.; Croft, B.Y.; Teates, C.D.; Plankey, M.W.; McCallum, R.W.
A noninvasive scintigraphic assessment of the colonic transit of nondigestible solids in man. J. Nucl. Med.
1991, 32, 1375–1381. [PubMed]
53. McLean, R.G.; Smart, R.C.; Gaston-Parry, D.; Barbagallo, S.; Baker, J.; Lyons, N.R.; Bruck, C.E.;
King, D.W.; Lubowski, D.Z.; Talley, N.A. Colon transit scintigraphy in health and constipation using
oral iodine-131-cellulose. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 1990, 31, 985–989.
54. Smart, R.C.; McLean, R.G.; Gaston-Parry, D.; Barbagallo, S.; Bruck, C.E.; King, D.W.; Lubowski, D.Z.;
Talley, N.A. Comparison of oral iodine-131-cellulose and indium-111-DTPA as tracers for colon transit
scintigraphy: Analysis by colon activity profiles. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 1991, 32, 1668–1674.
55. Kekilli, E.; Yagmur, C.; Isik, B.; Aydin, O.M. Calculating colon transit time with radionuclide-filled capsules
in constipated patients: A new method for colon transit study. Abdom. Imaging 2005, 30, 593–597. [CrossRef]
56. Wagner, R.H.; Savir-Baruch, B.; Halama, J.R.; Venu, M.; Gabriel, M.S.; Bova, D. Proof of concept: Design and
initial evaluation of a device to measure gastrointestinal transit time. J. Nucl. Med. Technol. 2017, 45, 230–235.
[CrossRef]
57. Wagner, R.; Halama, J.; Venu, M.; Bova, D.; Savir-Baruch, B.; Gabriel, M. A point source device to determine
small and large bowel transit time-proof of concept and initial results. J. Nucl. Med. 2016, 57, 649.
58. Eising, E.G.; von der Ohe, M.R. Differentiation of prolonged colonic transit using scintigraphy with
indium-111-labeled polystyrene pellets. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 1998, 39, 1062–1066.
59. Deiteren, A.; Camilleri, M.; Bharucha, A.E.; Burton, D.; McKinzie, S.; Rao, A.S.; Zinsmeister, A.R. Performance
characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and
relationship to bowel functions. Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc. 2010, 22,
415-e95. [CrossRef]
60. Cremonini, F.; Mullan, B.P.; Camilleri, M.; Burton, D.D.; Rank, M.R. Performance characteristics of
scintigraphic transit measurements for studies of experimental therapies. Aliment. Pharmacol. Ther.
2002, 16, 1781–1790. [CrossRef]
61. Lin, H.C.; Prather, C.; Fisher, R.S.; Meyer, J.H.; Summers, R.W.; Pimentel, M.; McCallum, R.W.;
Akkermans, L.M.A.; Loening-Baucke, V.; AMS Task Force Committee on Gastrointestinal Transit.
Measurement of gastrointestinal transit. Dig. Dis. Sci. 2005, 50, 989–1004. [CrossRef] [PubMed]
62. Maqbool, S.; Parkman, H.P.; Friedenberg, F.K. Wireless capsule motility: Comparison of the smartPill GI
monitoring system with scintigraphy for measuring whole gut transit. Dig. Dis. Sci. 2009, 54, 2167–2174.
[CrossRef] [PubMed]
63. Basile, M.; Neri, M.; Carriero, A.; Casciardi, S.; Comani, S.; Delgratta, C.; Didonato, L.; Diluzio, S.; Macri, M.A.;
Pasquarelli, A.; et al. Measurement of segmental transit through the gut in man. A novel approach by the
biomagnetic method. Dig. Dis. Sci. 1992, 37, 1537–1543. [CrossRef] [PubMed]
64. Worsoe, J.; Fynne, L.; Gregersen, T.; Schlageter, V.; Christensen, L.A.; Dahlerup, J.F.; Rijkhoff, N.J.M.;
Laurberg, S.; Krogh, K. Gastric transit and small intestinal transit time and motility assessed by a magnet
tracking system. Bmc Gastroenterol. 2011, 11. [CrossRef] [PubMed]
65. Weitschies, W.; Blume, H.; Mönnikes, H. Magnetic Marker Monitoring: High resolution real-time tracking of
oral solid dosage forms in the gastrointestinal tract. Eur. J. Pharm. Biopharm. 2010, 74, 93–101. [CrossRef]
[PubMed]
66. Hiroz, P.; Schlageter, V.; Givel, J.C.; Kucera, P. Colonic movements in healthy subjects as monitored by a
Magnet Tracking System. Neurogastroenterol. Motil. 2009, 21, 838-e57. [CrossRef] [PubMed]
67. Haase, A.M.; Fallet, S.; Otto, M.; Scott, S.M.; Schlageter, V.; Krogh, K. Gastrointestinal motility during
sleep assessed by tracking of telemetric capsules combined with polysomnography—a pilot study.
Clin. Exp. Gastroenterol. 2015, 8, 327–332. [CrossRef]
68. Haase, A.M.; Gregersen, T.; Schlageter, V.; Scott, M.S.; Demierre, M.; Kucera, P.; Dahlerup, J.F.; Krogh, K.
Pilot study trialling a new ambulatory method for the clinical assessment of regional gastrointestinal transit
using multiple electromagnetic capsules. Neurogastroenterol. Motil. 2014, 26, 1783–1791. [CrossRef]
Diagnostics 2019, 9, 0221 15 of 15
69. Mark, E.B.; Poulsen, J.L.; Haase, A.M.; Frokjaer, J.B.; Schlageter, V.; Scott, S.M.; Krogh, K.; Drewes, A.M.
Assessment of colorectal length using the electromagnetic capsule tracking system: A comparative validation
study in healthy subjects. Colorectal Dis. 2017, 19, O350–O357. [CrossRef]
70. Mark, E.B.; Poulsen, J.L.; Haase, A.M.; Espersen, M.; Gregersen, T.; Schlageter, V.; Scott, S.M.; Krogh, K.;
Drewes, A.M. Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system.
Neurogastroenterol. Motil. 2019, 31. [CrossRef]
71. Chaddock, G.; Lam, C.; Hoad, C.L.; Costigan, C.; Cox, E.F.; Placidi, E.; Thexton, I.; Wright, J.; Blackshaw, P.E.;
Perkins, A.C.; et al. Novel MRI tests of orocecal transit time and whole gut transit time: Studies in normal
subjects. Neurogastroenterol. Motil. 2014, 26, 205–214. [CrossRef] [PubMed]
72. Lam, C.; Chaddock, G.; Hoad, C.L.; Costigan, C.; Cox, E.; Marciani, L.; Gowland, P.A.; Spiller, R.C. A new
validated MRI method for measuring whole gut transit time. Gastroenterology 2013, 144, S920. [CrossRef]
73. Lam, C.; Chaddock, G.; Marciani, L.; Costigan, C.; Paul, J.; Cox, E.; Hoad, C.; Menys, A.; Pritchard, S.;
Garsed, K.; et al. Colonic response to laxative ingestion as assessed by MRI differs in constipated irritable
bowel syndrome compared to functional constipation. Neurogastroenterol. Motil. 2016, 28, 861–870. [CrossRef]
[PubMed]
74. Lam, C.; Chaddock, G.; Marciani Laurea, L.; Costigan, C.; Cox, E.; Hoad, C.; Pritchard, S.; Gowland, P.;
Spiller, R. Distinct Abnormalities of Small Bowel and Regional Colonic Volumes in Subtypes of Irritable
Bowel Syndrome Revealed by MRI. Am. J. Gastroenterol. 2017, 112, 346–355. [CrossRef]
75. Buhmann, S.; Kirchhoff, C.; Ladurner, R.; Mussack, T.; Reiser, M.F.; Lienemann, A. Assessment of colonic
transit time using MRI: A feasibility study. Eur. Radiol. 2007, 17, 669–674. [CrossRef]
76. Zhi, M.; Zhou, Z.; Chen, H.; Xiong, F.; Huang, J.; He, H.; Zhang, M.; Su, M.; Gao, X.; Hu, P. Clinical
application of a gadolinium-based capsule as an MRI contrast agent in slow transit constipation diagnostics.
Neurogastroenterol. Motil. 2017, 29, e13020. [CrossRef]
77. Patak, M.A.; Weishaupt, D.; Frohlich, J.M.; Debatin, J.F. Sequential fast 3D MRI following oral ingestion
of Gd-DOTA: A new means to assess intestinal transit time. J. Magn. Reson. Imaging 1999, 10, 474–476.
[CrossRef]
78. Hahn, T.; Kozerke, S.; Schwizer, W.; Fried, M.; Boesiger, P.; Steingoetter, A. Visualization and quantification
of intestinal transit and motor function by real-time tracking of 19F labeled capsules in humans.
Magn. Reson. Med. 2011, 66, 812–820. [CrossRef]
79. Yeong, C.H.; Abdullah, B.J.J.; Ng, K.H.; Chung, L.Y.; Goh, K.L.; Perkins, A.C. Fusion of gamma scintigraphic
and magnetic resonance images improves the anatomical delineation of radiotracer for the assessment of
gastrointestinal transit. Nucl. Med. Commun. 2013, 34, 645–651. [CrossRef]
80. Pritchard, S.E.; Marciani, L.; Garsed, K.C.; Hoad, C.L.; Thongborisute, W.; Roberts, E.; Gowland, P.A.;
Spiller, R.C. Fasting and postprandial volumes of the undisturbed colon: Normal values and changes in
diarrhea-predominant irritable bowel syndrome measured using serial MRI. Neurogastroenterol. Motil. 2013,
26, 124–130. [CrossRef]
81. Nilsson, M.; Sandberg, T.H.; Poulsen, J.L.; Gram, M.; Frøkjaer, J.B.; Østergaard, L.R.; Krogh, K.; Brock, C.;
Drewes, A.M. Quantification and variability in colonic volume with a novel magnetic resonance imaging
method. Neurogastroenterol. Motil. 2015, 27, 1755–1763. [CrossRef] [PubMed]
82. Kim, E.R.; Rhee, P.-L. How to Interpret a Functional or Motility Test—Colon Transit Study.
J. Neurogastroenterol. Motil. 2012, 18, 94–99. [CrossRef] [PubMed]
83. Rao, S.S.C.; Meduri, K. What is necessary to diagnose constipation? Best Pract. Res. Clin. Gastroenterol. 2011,
25, 127–140. [CrossRef] [PubMed]
84. Keller, J.; Bassotti, G.; Clarke, J.; Dinning, P.; Fox, M.; Grover, M.; Hellstrom, P.M.; Ke, M.Y.; Layer, P.;
Malagelada, C.; et al. Advances in the diagnosis and classification of gastric and intestinal motility disorders.
Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 291–308. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
